MolecuLight® improves success with
Pressure Injuries

A retrospective review across 55 long-term care facilities showing that MolecuLight significantly improved pressure injury outcomes compared to standard care alone. Patients treated with MolecuLight experienced a 71% higher healing rate, healed 28% faster, were 1.4 to 1.8 times more likely to heal, and experienced 75% fewer complications.

A retrospective review across 55 long-term care facilities showing that MolecuLight significantly improved pressure injury outcomes compared to standard care alone. Patients treated with MolecuLight experienced a 71% higher healing rate, healed 28% faster, were 1.4 to 1.8 times more likely to heal, and experienced 75% fewer complications.

Fluorescence imaging enabled real-time monitoring of bacterial burden, guiding adjustments to NPWT and biofilm-disrupting agent treatments in recalcitrant pressure ulcer care.

MolecuLight precisely identified bacteria in pelvic pressure injuries (PIs), enhancing the understanding of PI infections, guiding treatment strategies like debridement and dressing adjustments, and enabling real-time monitoring of treatment efficacy.